OBJECTIVE Identify determinants of weight gain in people with type 2 diabetes mellitus
(T2DM) allocated to intensive versus standard glycemic control in the Action to Control …

OBJECTIVE Intensive treatment (INT) of type 1 diabetes reduces the incidence of
cardiovascular disease (CVD) events compared with conventional treatment (CONV), but it …

OBJECTIVE Moderate weight gain is usual after starting insulin therapy. The identification
and quantification of factors associated with weight gain may help target strategies for …

OBJECTIVE Short-term weight loss improves cardiovascular disease (CVD) risk factors. We
sought to determine the longer-term effects of maintaining weight loss or, conversely …

Aims: To determine the baseline characteristics and glucose‐lowering therapies associated
with weight change among patients with type 2 diabetes. Methods: Eleven thousand one …

OBJECTIVE—Weight loss in type 2 diabetes is undisputedly important, and data from
community settings are limited. We evaluated weight change and resulting glycemic and …

OBJECTIVE—The effectiveness of intentional weight loss in reducing cardiovascular
disease (CVD) events in type 2 diabetes is unknown. This report describes 1-year changes …

Aims This study evaluates the relationship between HbA1c and weight change outcomes by
anti-diabetic weight-effect properties in patients newly treated for type 2 diabetes; a …

Aims To examine body mass index (BMI) and HbA1c for individuals with type 2 diabetes
(T2D) in the United States. Methods The retrospective study utilized data from IBM® …

OBJECTIVE This study examined specific measures of weight loss in relation to incident
diabetes and improvement in cardiometabolic risk factors. RESEARCH DESIGN AND …